Last reviewed · How we verify
Lansoprazole/Domperidone
Lansoprazole reduces stomach acid by inhibiting the proton pump, while domperidone enhances gastric motility and prevents nausea by blocking dopamine receptors.
Lansoprazole reduces stomach acid by inhibiting the proton pump, while domperidone enhances gastric motility and prevents nausea by blocking dopamine receptors. Used for Gastroesophageal reflux disease (GERD) with associated nausea or dysmotility, Peptic ulcer disease with gastric dysmotility, Functional dyspepsia with acid reflux.
At a glance
| Generic name | Lansoprazole/Domperidone |
|---|---|
| Also known as | Duolans |
| Sponsor | Neutec Ar-Ge San ve Tic A.Ş |
| Drug class | Proton pump inhibitor + dopamine antagonist combination |
| Target | H+/K+-ATPase (lansoprazole); dopamine D2/D3 receptors (domperidone) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Lansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking H+/K+-ATPase in parietal cells. Domperidone is a peripheral dopamine antagonist that increases gastric contractions and accelerates gastric emptying while reducing nausea and vomiting. Together, they provide dual action for acid-related disorders with improved gastric function.
Approved indications
- Gastroesophageal reflux disease (GERD) with associated nausea or dysmotility
- Peptic ulcer disease with gastric dysmotility
- Functional dyspepsia with acid reflux
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Dizziness
Key clinical trials
- Cardiac Safety of Lansoprazole and Domperidon Combination (PHASE4)
- A New System for GERD Diagnosis and Treatment
- The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity (PHASE4)
- Prophylaxis for Aspiration of Gastric Contents. (PHASE4)
- An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lansoprazole/Domperidone CI brief — competitive landscape report
- Lansoprazole/Domperidone updates RSS · CI watch RSS
- Neutec Ar-Ge San ve Tic A.Ş portfolio CI